PMID- 29149303
OWN - NLM
STAT- MEDLINE
DCOM- 20190412
LR  - 20240323
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Print)
IS  - 0022-1899 (Linking)
VI  - 217
IP  - 2
DP  - 2018 Jan 4
TI  - Changes in Cytokine, Filarial Antigen, and DNA Levels Associated With Adverse 
      Events Following Treatment of Lymphatic Filariasis.
PG  - 280-287
LID - 10.1093/infdis/jix578 [doi]
AB  - BACKGROUND: Mild to moderate adverse events (AEs) are common after treatment of 
      lymphatic filariasis (LF) and pose a major challenge for the global LF 
      elimination program. We studied changes in cytokine levels and filarial worm 
      components in plasma of subjects with and without AEs following treatment of LF. 
      METHODS: Participants (n = 24) were hospitalized and monitored for AEs following 
      treatment. Cytokines (27), filarial DNA, circulating filarial antigen (CFA), and 
      immune complexes were measured in plasma samples collected before and after 
      treatment. RESULTS: Levels for 16 cytokines increased after treatment in 
      individuals with moderate AEs compared to individuals with no and/or mild AEs. 
      These included 3 major proinflammatory cytokines (interleukin 6, tumor necrosis 
      factor alpha, and interleukin 1beta). Eotaxin-1 levels were elevated at baseline in 
      individuals who developed moderate AEs after treatment; thus, eotaxin-1 is a 
      potential biomarker for AE risk. CFA and filarial DNA levels increased more in 
      individuals with moderate AEs after treatment than in people with no/mild AEs. 
      CONCLUSIONS: Increases in cytokine, filarial DNA, and CFA levels were associated 
      with development of AEs following treatment of LF. Improved understanding of the 
      pathogenesis of AEs may lead to improved methods for their prevention or 
      management that could increase compliance in elimination programs.
CI  - (c) The Author 2017. Published by Oxford University Press for the Infectious 
      Diseases Society of America.
FAU - Andersen, Britt J
AU  - Andersen BJ
AD  - Infectious Diseases Division, Department of Medicine, Washington University 
      School of Medicine, St Louis, Missouri.
FAU - Kumar, Jessica
AU  - Kumar J
AD  - Center for Global Health and Diseases, Case Western Reserve University School of 
      Medicine, Cleveland, Ohio.
FAU - Curtis, Kurt
AU  - Curtis K
AD  - Infectious Diseases Division, Department of Medicine, Washington University 
      School of Medicine, St Louis, Missouri.
FAU - Sanuku, Nelly
AU  - Sanuku N
AD  - Papua New Guinea Institute of Medical Research, Goroka.
FAU - Satofan, Samson
AU  - Satofan S
AD  - Papua New Guinea Institute of Medical Research, Goroka.
FAU - King, Christopher L
AU  - King CL
AD  - Center for Global Health and Diseases, Case Western Reserve University School of 
      Medicine, Cleveland, Ohio.
FAU - Fischer, Peter U
AU  - Fischer PU
AD  - Infectious Diseases Division, Department of Medicine, Washington University 
      School of Medicine, St Louis, Missouri.
FAU - Weil, Gary J
AU  - Weil GJ
AD  - Infectious Diseases Division, Department of Medicine, Washington University 
      School of Medicine, St Louis, Missouri.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Antigen-Antibody Complex)
RN  - 0 (Antigens, Helminth)
RN  - 0 (Cytokines)
RN  - 0 (DNA, Helminth)
RN  - 0 (Filaricides)
SB  - IM
EIN - J Infect Dis. 2018 Mar 28;217(8):1334. PMID: 29584877
MH  - Antigen-Antibody Complex/blood
MH  - Antigens, Helminth/*blood
MH  - Cytokines/*blood
MH  - DNA, Helminth/*blood
MH  - Drug-Related Side Effects and Adverse Reactions/pathology
MH  - Elephantiasis, Filarial/*drug therapy/*pathology
MH  - Filaricides/administration & dosage/*adverse effects
MH  - Humans
MH  - Plasma/chemistry
PMC - PMC5853815
OTO - NOTNLM
OT  - adverse events
OT  - circulating filarial antigenemia
OT  - cytokines
OT  - lymphatic filariasis
OT  - therapy
EDAT- 2017/11/18 06:00
MHDA- 2019/04/13 06:00
PMCR- 2017/11/15
CRDT- 2017/11/18 06:00
PHST- 2017/09/18 00:00 [received]
PHST- 2017/11/13 00:00 [accepted]
PHST- 2017/11/18 06:00 [pubmed]
PHST- 2019/04/13 06:00 [medline]
PHST- 2017/11/18 06:00 [entrez]
PHST- 2017/11/15 00:00 [pmc-release]
AID - 4628135 [pii]
AID - jix578 [pii]
AID - 10.1093/infdis/jix578 [doi]
PST - ppublish
SO  - J Infect Dis. 2018 Jan 4;217(2):280-287. doi: 10.1093/infdis/jix578.